Literature DB >> 2317492

Liposomes with entrapped doxorubicin exhibit extended blood residence times.

M B Bally1, R Nayar, D Masin, M J Hope, P R Cullis, L D Mayer.   

Abstract

The blood residence time of liposomes with entrapped doxorubicin is shown to be significantly longer than for identically prepared empty liposomes. Liposomal doxorubicin systems with a drug-to-lipid ratio of 0.2 (w/w) were administered at a dose of 100 mg lipid/kg. Both doxorubicin and liposomal lipid were quantified in order to assess in vivo stability and blood residence times. For empty vesicles composed of phosphatidylcholine (PC)/cholesterol (55:45, mole ratio) and sized through filters of 100 nm pore size, 15-25% of the administered lipid dose was recovered in the blood 24 h after i.v. injection. The percentage of the dose retained in the circulation at 24 h increased 2-3-fold when the liposomes contain entrapped doxorubicin. For 100 nm distearoyl PC/chol liposomal doxorubicin systems, as much as 80% of the injected dose of lipid and drug remain within the blood compartment 24 h after i.v. administration.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2317492     DOI: 10.1016/0005-2736(90)90018-j

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  11 in total

Review 1.  Liposomal drug delivery. Advantages and limitations from a clinical pharmacokinetic and therapeutic perspective.

Authors:  R M Fielding
Journal:  Clin Pharmacokinet       Date:  1991-09       Impact factor: 6.447

2.  Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy.

Authors:  D Papahadjopoulos; T M Allen; A Gabizon; E Mayhew; K Matthay; S K Huang; K D Lee; M C Woodle; D D Lasic; C Redemann
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-15       Impact factor: 11.205

3.  Uptake and metabolism of lipoprotein-X in mesangial cells.

Authors:  E G Lynn; P C Choy; A Magil; K O
Journal:  Mol Cell Biochem       Date:  1997-10       Impact factor: 3.396

Review 4.  Photochemical mechanisms of light-triggered release from nanocarriers.

Authors:  Nadezda Fomina; Jagadis Sankaranarayanan; Adah Almutairi
Journal:  Adv Drug Deliv Rev       Date:  2012-02-22       Impact factor: 15.470

5.  Studies on the myelosuppressive activity of doxorubicin entrapped in liposomes.

Authors:  M B Bally; R Nayar; D Masin; P R Cullis; L D Mayer
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

6.  Transfer of liposomal drug carriers from the blood to the peritoneal cavity of normal and ascitic tumor-bearing mice.

Authors:  M B Bally; D Masin; R Nayar; P R Cullis; L D Mayer
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

Review 7.  Liposomes as carriers of cancer chemotherapy. Current status and future prospects.

Authors:  S Kim
Journal:  Drugs       Date:  1993-10       Impact factor: 9.546

8.  A two-step targeting approach for delivery of doxorubicin-loaded liposomes to tumour cells in vivo.

Authors:  S A Longman; P R Cullis; L Choi; G de Jong; M B Bally
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

9.  Improved pharmacokinetics and efficacy of a highly stable nanoliposomal vinorelbine.

Authors:  Daryl C Drummond; Charles O Noble; Zexiong Guo; Mark E Hayes; John W Park; Ching-Ju Ou; Yun-Long Tseng; Keelung Hong; Dmitri B Kirpotin
Journal:  J Pharmacol Exp Ther       Date:  2008-10-23       Impact factor: 4.030

10.  Identification of vesicle properties that enhance the antitumour activity of liposomal vincristine against murine L1210 leukemia.

Authors:  L D Mayer; R Nayar; R L Thies; N L Boman; P R Cullis; M B Bally
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.